Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomised controlled trial to explore the effectiveness and cost-effectiveness of a patient-initiated botulinum toxin treatment model for blepharospasm and hemifacial Spasm compared to treatment as usual

Next Previous
Search
Trial Profile

A randomised controlled trial to explore the effectiveness and cost-effectiveness of a patient-initiated botulinum toxin treatment model for blepharospasm and hemifacial Spasm compared to treatment as usual

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Jun 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Botulinum-Toxin-A (Primary)
  • Indications Blepharospasm; Hemifacial spasm
  • Focus Therapeutic Use
  • Sponsors Merz Pharma

Most Recent Events

  • 13 Jun 2016 Planned End Date changed from 15 Apr 2016 to 15 Jun 2016.
  • 04 Nov 2015 Accrual to date is 23% according to United Kingdom Clinical Research Network record.
  • 04 Nov 2015 Accrual to date is 15% according to United Kingdom Clinical Research Network record.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top